Rhythm Pharmaceuticals, INC Form 4 insider transactions

Edward T. Mathers, a Director at Rhythm Pharmaceuticals, Inc., reported the vesting of 4,000 restricted stock units and a net disposition of 3,000 common shares, resulting in an indirect beneficial ownership of 5,771 shares.

Christophe Jean, a Director at Rhythm Pharmaceuticals, Inc., disposed of 7,000 common shares on June 18, 2025, following the vesting of 4,000 restricted stock units.

Jennifer L. Good, a Director at Rhythm Pharmaceuticals, Inc., acquired 4,000 shares of common stock following the vesting of restricted stock units.

Camille L. Bedrosian, a Director at Rhythm Pharmaceuticals, Inc., disposed of 7,000 common shares on June 18, 2025, following the vesting and conversion of 4,000 restricted stock units.

Rhythm Pharmaceuticals, Inc. Director Stuart A. Arbuckle reported the vesting of 4,000 restricted stock units and the subsequent disposition of 7,000 common shares, resulting in zero beneficial ownership.

David W.J. McGirr, a Director at Rhythm Pharmaceuticals, Inc., acquired 4,000 shares of common stock through the vesting and conversion of Restricted Stock Units.

Lynn A. Tetrault, a Director at Rhythm Pharmaceuticals, Inc. (RYTM), reported the vesting and acquisition of 4,000 common shares from Restricted Stock Units, alongside a disposition of 7,000 common shares, resulting in a net reduction of 3,000 shares on June 18, 2025.

Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, Inc., executed a pre-arranged transaction involving the exercise of stock options and the subsequent sale of common stock.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc., executed a planned sale of 7,031 common shares after exercising stock options on June 6, 2025.

A director at Rhythm Pharmaceuticals, David W.J. McGirr, exercised stock options and subsequently sold a significant number of common shares, reducing his direct beneficial ownership.

Rhythm Pharmaceuticals' President and CEO, David P. Meeker, exercised stock options and subsequently sold an equivalent number of shares under a Rule 10b5-1 plan, while also acquiring additional shares through an employee stock purchase plan.

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, exercised stock options and subsequently sold a portion of his common stock holdings on May 30, 2025, pursuant to a pre-arranged Rule 10b5-1 plan.

Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, sold 6,745 shares of common stock at an average price of $65.0773 under a pre-arranged 10b5-1 trading plan.

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, reports the vesting and disposal of restricted stock units.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, sold shares of common stock on April 8, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, exercised restricted stock units and sold shares to cover withholding taxes on March 20 and 21, 2025.

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Hunter C. Smith, CFO of Rhythm Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units.

Chief Technical Officer Joseph Shulman reports acquisition and disposal of Rhythm Pharmaceuticals stock and derivative securities.

David Meeker, CEO of Rhythm Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities, including stock options and restricted stock units.

EVP, Head of International at Rhythm Pharmaceuticals, Yann Mazabraud, reports the vesting of restricted stock units and the grant of stock options.

Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units.

Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Pamela Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, reports the acquisition and disposal of company stock and derivative securities.

Hunter C. Smith, CFO of Rhythm Pharmaceuticals, sold a portion of his common stock to cover withholding taxes related to vesting restricted stock units.

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, sold shares of common stock on February 12, 2025, to cover withholding taxes related to vesting restricted stock units.

EVP Jennifer Kayden Lee of Rhythm Pharmaceuticals sold shares of common stock on February 12th and 13th, 2025, to cover withholding taxes and under a pre-arranged 10b5-1 trading plan.